About Galactokinase
Galactokinase (GALK1) is a protein
from Homo sapiens identified by UniProt accession
P51570, 392 residues long.
MolForge cross-references it against 0 known binders and
104 disease associations.
Target properties
| Protein name | Galactokinase |
| UniProt accession | P51570 |
| Gene | GALK1 |
| Organism | Homo sapiens |
| Length | 392 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (104)
Diseases linked to this target (Open Targets).
- galactokinase deficiency · score 0.85
- junctional epidermolysis bullosa with pyloric atresia · score 0.53
- Junctional epidermolysis bullosa - pyloric atresia · score 0.53
- epidermolysis bullosa, junctional 5A, intermediate · score 0.47
- Localized epidermolysis bullosa simplex · score 0.35
- junctional epidermolysis bullosa, non-Herlitz type · score 0.35
- epidermolysis bullosa simplex 1C, localized · score 0.35
- Red cell distribution width · score 0.26
- genetic disorder · score 0.19
- sex hormone-binding globulin measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51570-F1 | alphafold | PREDICTED | 97.19 | — |
Amino-acid sequence (392 residues)
MAALRQPQVA ELLAEARRAF REEFGAEPEL AVSAPGRVNL IGEHTDYNQG LVLPMALELM TVLVGSPRKD GLVSLLTTSE GADEPQRLQF PLPTAQRSLE PGTPRWANYV KGVIQYYPAA PLPGFSAVVV SSVPLGGGLS SSASLEVATY TFLQQLCPDS GTIAARAQVC QQAEHSFAGM PCGIMDQFIS LMGQKGHALL IDCRSLETSL VPLSDPKLAV LITNSNVRHS LASSEYPVRR RQCEEVARAL GKESLREVQL EELEAARDLV SKEGFRRARH VVGEIRRTAQ AAAALRRGDY RAFGRLMVES HRSLRDDYEV SCPELDQLVE AALAVPGVYG SRMTGGGFGG CTVTLLEASA APHAMRHIQE HYGGTATFYL SQAADGAKVL CL
Explore Galactokinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets